01:06 PM EDT, 10/27/2026 (MT Newswires) -- Newbury Pharmaceuticals (NEWBRY.ST) secured Swedish marketing authorization for Prukalopride Newbury, a generic version of Resolor, for the symptomatic treatment of chronic constipation in adults. The authorization covers the pharmaceutical company's drug in 1-milligram and 2-mg film-coated tablets, according to a Tuesday release. The company has no plans for further country approvals at this time.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.